2022-502425-18-00招募中3 期
PEACE 6 Vulnerable : A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents.
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Unicancer
- 入组人数
- 313
- 试验地点
- 93
- 主要终点
- Radiographic progression-free survival, defined as time from randomisation to radiographic progression as assessed by the investigator according to PCWG3 criteria (Scher, 2016; Appendix 3), or death, whichever occurs first.
研究概览
简要总结
To compare the efficacy of ADT + darolutamide vs ADT + placebo in terms of radiographic progression-free survival in patients with castration-naïve de novo metastatic prostate cancer with vulnerable functional ability and not elected for docetaxel or other androgen receptor pathway inhibitors.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Signed a written informed consent form prior to any trial specific procedures.
- •For sexually active men, agreement to use adequate contraception for the duration of trial participation and up to 2 weeks after completing study treatment
- •Affiliated to the social security system or in possession of equivalent private health insurance (according to local regulations for participation in clinical trials)
- •Willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up.
- •Men with histologically or cytologically confirmed adenocarcinoma of the prostate.
- •Aged ≥18 years old at the time of signing informed consent
- •De novo metastatic disease defined by clinical or radiographic evidence of metastases.
- •Measurable disease or bone lesions that are evaluable according to PCWG3 criteria
- •Ineligible for treatment with all of the following drugs: docetaxel, abiraterone, enzalutamide, apalutamide; AND meets at least one of the frailty criteria
- •Adequate bone marrow function: haemoglobin ≥80g/L, white blood cells ≥ 3.0 x109/L and platelets ≥80 x109/L.
- •Adequate liver function: alanine aminotransferase (ALT) < 2 xULN and bilirubin < 1.5 xULN, (or if bilirubin is between 1.5-2x ULN, they must have a normal conjugated bilirubin). For patients with documented liver metastasis ALT < 5 xULN is acceptable
- •Adequate renal function: calculated creatinine clearance > 30 ml/min (using the MDRD or CKD EPI method)
排除标准
- •Three or more Grade 3, or any Grade 4 events on the CISR-G questionnaire.
- •Prior malignancy ≤ 3 years before study enrolment. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e., pTis, pTa, and pT1) is allowed, as well as any localized cancer for which treatment has been completed ≥6 months before randomisation and from which the subject has been disease-free, or for which the risk of relapse is less than 30%, as well as early stage chronic lymphocytic leukaemia that does not require any specific treatment.
- •Inability to swallow oral medications
- •Gastrointestinal disorder or procedure that can be expected to interfere significantly with the absorption of study treatment.
- •Known to have active viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver disease at screening.
- •Treatment with any investigational product within 28 days before randomisation.
- •Concurrent participation in another clinical trial involving an investigational product (patients enrolled in non-experimental trials with no modification of the standard of care can be included).
- •Individual of full age deprived of liberty or placed under a legal protection measure (tutorship/curatorship/temporary guardianship).
- •Significantly altered mental status prohibiting the understanding of the study or with psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule or any condition that, in the opinion of the investigator, would preclude participation in this trial.
- •Eastern Cooperative Oncology Group (ECOG) performance status score ≥3
- •Hypertension not controlled by an anti-hypertensive treatment (systolic blood pressure [BP] ≥ 160 mmHg or diastolic BP ≥ 95 mmHg; 3 consecutive measures taken 5 minutes apart).
- •Acute toxicities of prior treatments and procedures not resolved to grade ≤ 1 or baseline before randomisation with the exception of hot flushes and erectile dysfunction.
- •Previous systemic treatment for prostate cancer, except less than 12 weeks of ADT and/or an old-generation AR inhibitor.
- •Severe or uncontrolled concurrent disease, infection or co-morbidity.
- •Known hypersensitivity to the study treatment or any of its ingredients.
- •Major surgery within 28 days before randomisation.
- •Any of the following within 6 months before randomisation: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association (NYHA) Class III or IV.
结局指标
主要结局
Radiographic progression-free survival, defined as time from randomisation to radiographic progression as assessed by the investigator according to PCWG3 criteria (Scher, 2016; Appendix 3), or death, whichever occurs first.
Radiographic progression-free survival, defined as time from randomisation to radiographic progression as assessed by the investigator according to PCWG3 criteria (Scher, 2016; Appendix 3), or death, whichever occurs first.
次要结局
- Castration-resistant prostate cancer (CRPC)-free survival, defined as the time from randomisation to onset of CRPC according to PCWG3 criteria, or death, whichever occurs first.
- Clinical progression-free survival, defined as time from randomisation to first occurrence
- Overall survival, defined as the time from randomisation to the time of death from any cause. For subjects alive at the time of analysis, data will be censored on the last date the subject was known to be alive or lost to follow-up or withdraw consent.
- Toxicity will be evaluated according to version 5 of the National Cancer Institut - Common Terminology Criteria for Adverse Events
研究者
Director of regulatory Affairs and Pharmacovigilance
Scientific
Unicancer
研究点 (93)
Loading locations...
相似试验
招募中
3 期
Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial treatment and a maximum of 5 metastases.2022-502373-42-00UZ Leuven873
已完成
4 期
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis2023-504869-23-00AbbVie Deutschland GmbH & Co. KG272
已完成
不适用
Comparison Of Clinical And Radiological Success Of Pulpotomy Treatments Performed With Proroot MTA, NeoPUTTY MTA, TheraCal PT In Primary TeethNCT07260357Necmettin Erbakan University90
招募中
1 期
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor PatientsNCT07260305Kangabio AUSTRALIA LTD PTY57
招募中
3 期
Comparing two treatment regimen for sinuses tumors and salivary glands: radiotherapy versus chemoradiotherapy2024-513972-16-00Groupe Oncologie Radiotherapie Tete Cou342